Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1

Published:2020-07 Issue:7 Volume:62 Page:857-859
ISSN:1328-8067
Container-title:Pediatrics International
language:en
Short-container-title:Pediatrics International

Author:

Mateos Maria Elena¹²^ORCID,López‐Laso Eduardo²³,Vicente Josefina⁴,Ortega Rosa²⁵,Vázquez Fernando²⁶,Pérez‐Navero Juan Luis¹²

Affiliation:

1. Pediatric Oncology Unit Department of Pediatrics Reina Sofia University Hospital Córdoba Spain

2. Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC)Reina Sofia University Hospital Córdoba Spain

3. Neuropediatric UnitDepartment of PediatricsReina Sofia University Hospital Córdoba Spain

4. Pediatric Radiology Unit Department of Radiology Reina Sofia University Hospital Córdoba Spain

5. Department of Pathology Reina Sofia University Hospital Córdoba Spain

6. Department of Pediatric Surgery Reina Sofia University Hospital Córdoba Spain

Publisher

Wiley

Subject

Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ped.14183

Reference14 articles.

1. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas

2. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications

3. TOR Signaling in Growth and Metabolism

4. The NF1 tumor suppressor critically regulates TSC2 and mTOR

5. Review ArticLe : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Caveat mammalian target of rapamycin (mTOR) revisited: Neurofibromatosis;Journal of the American Academy of Dermatology;2023-04

2. Neurofibromatosis type 1 system-based manifestations and treatments: a review;Neurological Sciences;2023-02-24

3. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials;Expert Opinion on Investigational Drugs;2021-12-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3